INVOKANA ® (canagliflozin) Significantly Reduces the Risk of Heart Failure- Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news